The denial almost always traces back to your insurance plan, not to Hims.
Hims generally doesn't bill insurance directly for GLP-1 medication in most cases, so what you're navigating is your plan's own coverage rules — formulary exclusions, diagnosis coding, or prior authorization requirements.
If your plan excludes weight-loss GLP-1s as a category, switching telehealth providers won't change the outcome. A flat-rate option like Luma Health's $297/month tirzepatide sidesteps the insurance question entirely.
If your GLP-1 claim was denied while using Hims, or you're bracing for a denial before you even submit, you're dealing with one of the most common friction points in weight-loss telehealth right now. This page walks through why denials happen, what you can do about one, and when it makes more sense to stop fighting your insurer and switch to a flat-rate, insurance-independent path instead.
Why GLP-1 Insurance Claims Get Denied
Most denials trace back to one of a handful of causes, and none of them are unique to Hims. First, formulary exclusion: many employer plans specifically carve out anti-obesity medications as a category, meaning the plan document itself excludes coverage regardless of medical necessity. Second, diagnosis mismatch: a claim coded for weight loss is treated differently than one coded for type 2 diabetes, even when the medication is identical. Third, prior authorization and step therapy: even plans that do cover GLP-1s for obesity often require documented BMI thresholds, a history of failed alternative treatments, or physician-submitted clinical justification. Fourth, employer-level policy changes: some employers have scaled back GLP-1 coverage entirely as costs have risen, independent of anything you did.
Telehealth providers like Hims generally don't bill insurance directly for the medication itself in most cases, so what you're often navigating is a reimbursement or coverage-verification process on your plan's terms, not a decision Hims controls.
The coverage landscape, in 2025
The takeaway is blunt: even among employers who cover GLP-1s at all, coverage is concentrated at the largest companies and frequently narrowed with BMI thresholds, step-therapy rules, or diabetes-only restrictions. A denial today doesn't necessarily reflect an error — it may reflect a genuine and increasingly common plan design choice.
Coverage by Plan Type: What to Expect
| Plan Type | Typical Coverage | What Usually Gets Denied |
|---|---|---|
| Large employer (5,000+) | Increasingly common (~43%) | Claims without documented BMI/comorbidity |
| Small/mid employer (200+) | Less common (~19%) | Weight-loss indication entirely, if excluded |
| ACA Marketplace | Rare for obesity-specific brands | Almost all weight-loss-coded claims |
| Medicare Part D | Not covered for weight loss by law | Any weight-loss-coded claim |
| Medicaid | State-optional; varies widely | Depends entirely on state |
Two Ways Forward
- Worth it if your plan covers GLP-1s but denied on a technicality
- Requires your prescriber's cooperation to resubmit documentation
- Can take several weeks to a few months to resolve
- More likely to succeed with plans that already cover the category
- Makes sense if your plan excludes anti-obesity coverage outright
- Removes prior authorization and diagnosis-code friction entirely
- Trades a possible copay for a predictable flat monthly price
- Best if you've already spent weeks fighting a denial
How to Appeal a GLP-1 Denial: 5 Steps
1. Get the denial letter and read the stated reason. This tells you whether you're fighting a documentation gap or a hard exclusion, which changes your odds completely.
2. Call your insurer and ask directly whether weight-loss GLP-1s are excluded at the plan level. If yes, an appeal is very unlikely to succeed no matter how well-documented your case is.
3. If it's not a hard exclusion, work with your prescriber to resubmit with complete documentation: BMI, relevant comorbidities, and any required step-therapy history.
4. File a formal appeal in writing within your plan's stated window, and request an expedited review if going without medication poses a clinical concern.
5. Set a decision deadline for yourself. If you're several weeks in with no resolution, start pricing a flat-rate self-pay option in parallel.
Who Should Appeal vs. Switch to Flat-Rate
Luma Health's compounded semaglutide and tirzepatide are priced flat at $197/month and $297/month respectively, regardless of insurance status, diagnosis code, or plan-level exclusions, because the medication isn't billed through insurance at all. That's a real tradeoff: you give up the possibility of a low copay if your plan would have covered you, in exchange for a price that doesn't depend on anyone else's approval.
Every patient starts with a real medical evaluation from a licensed provider. Compounded semaglutide is $197/month and compounded tirzepatide is $297/month, flat, with no insurance billing and no prior authorization to wait on. Prepared by VialsRX, TX Board #35264, verifiable directly with the board. See all treatment options →
Skip the insurance fight,
pay one flat price
$197/month semaglutide. $297/month tirzepatide. No prior authorization, no denials, no waiting.
Get Started → Or start your free health assessmentWhat the Clinical Evidence Actually Supports
Insurance coverage decisions are a completely separate question from whether these medications work. It's worth remembering that while you're navigating a denial, since the frustration of a coverage fight can make it easy to lose sight of the underlying treatment decision.
Semaglutide's weight-loss efficacy was established in the STEP program, with the STEP 1 trial showing average weight reductions of roughly 15% over 68 weeks in adults with obesity. Its cardiovascular benefit in patients with established cardiovascular disease was separately confirmed in the SELECT trial, which followed over 17,000 patients and found a meaningful reduction in major adverse cardiovascular events independent of how much weight participants lost. Tirzepatide's data comes primarily from the SURMOUNT program, with SURMOUNT-1 showing average weight reductions ranging from 15% to nearly 21% depending on dose, the highest of any FDA-approved obesity medication to date.
None of this changes based on whether your insurance approves or denies a claim, or whether you end up on a compounded or brand-name version of the medication. The active pharmaceutical ingredient, and the clinical evidence behind it, stays the same regardless of the billing pathway you end up on.
Frequently Asked Questions
The denial almost always originates with your insurance plan's own coverage rules, not with Hims. Hims generally doesn't bill insurance directly for the medication in most cases, so you're navigating your plan's process on your plan's terms.
Yes, if the denial was based on missing documentation or an incomplete prior authorization. If your insurer confirms a hard category exclusion, an appeal is unlikely to succeed regardless of documentation.
Commonly several weeks to a few months. Ask your insurer about an expedited appeal if going without medication poses a clinical concern.
Depends on how likely your appeal is to succeed. If your plan has a hard exclusion, cash-pay through a flat-rate provider is usually faster and more predictable. If your plan covers the category and you were denied on a fixable technicality, a successful appeal could mean a copay well below any flat-rate price.
Not currently. Medicare Part D is prohibited by law from covering medications used specifically for weight loss, though it covers GLP-1s prescribed for other approved indications like type 2 diabetes.
Yes. Compounded semaglutide and tirzepatide through a provider like Luma Health are billed directly to you, not through insurance, so there's no prior authorization or formulary exclusion to navigate.
References
- Peterson-KFF Health System Tracker. Perspectives from Employers on the Costs and Issues Associated with Covering GLP-1 Agonists for Weight Loss (2025). healthsystemtracker.org
- KFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug (2025). kff.org
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- Texas State Board of Pharmacy. License Verification — VialsRX #35264. pharmacy.texas.gov